Document is current
Any future updates will be listed below
-
Authors
Cohen, Raphael
Duval, Vincent
Al-Rifai, Rida
Maryam, Sidrah
Santos-Zas, Icia https://orcid.org/0000-0002-0310-9074
Braik, Rayan https://orcid.org/0000-0003-1011-7256
Diedisheim, Marc https://orcid.org/0000-0002-0418-1107
Jouve, Charlène https://orcid.org/0000-0002-5792-4621
Nicoletti, Simon
Thietart, Sara
Guyon, Théo
Chetrit, Luna https://orcid.org/0009-0006-2161-1996
Kral, Maria
Döring, Yvonne https://orcid.org/0000-0001-9307-3396
Weber, Christian
Loupy, Alexandre
Domenge, Orianne
Livrozet, Marine
Hulot, Jean-Sebastien https://orcid.org/0000-0001-5463-6117
Sakalli, Ecem T.
Rizzo, Giuseppe https://orcid.org/0009-0008-5366-0738
Saliba, Antoine-Emmanuel https://orcid.org/0000-0001-8539-2784
Piollet, Marie
Bruneval, Patrick https://orcid.org/0000-0002-2350-2914
Tedgui, Alain https://orcid.org/0000-0002-7229-4875
Taleb, Soraya https://orcid.org/0000-0002-6650-619X
Hermine, Olivier
Wicks, Ian https://orcid.org/0000-0001-7050-6822
Silvestre, Jean-Sébastien https://orcid.org/0000-0003-3962-2205
Hayat, Sikander https://orcid.org/0000-0001-5919-8371
Cochain, Clement https://orcid.org/0000-0002-0340-1745
Vivier, Eric https://orcid.org/0000-0001-7022-8287
Ait-Oufella, Hafid https://orcid.org/0000-0002-2955-0183
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-18-CE14-0009)
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 19 March 2026
First Online: 1 April 2026
Competing interests
: H.A.-O. and V.D. applied a patent on the protective effect of NK depletion blockade after acute myocardial infarction. The other authors report no conflicts. H.A.-O. is co-founder of POLYGON therapeutics, a biotech developing monoclonal antibodies against cytotoxic cells. E.V. is co-founder of Innate Pharma, a biotech developing antibodies targeting NK cells in Cancer field. The remaining authors declare no competing interests.
